References
- Beckett A. H., Rowland M. Urinary excretion kinetics of methylamphetamine in man. Journal of Pharmacy and Pharmacology 1965; 17(Suppl.)109s–114s
- Brater D. C., Chennavasin P. Effects of renal disease: Pharmacokinetic considerations. Pharmacokinetic Basis for Drug Treatment, L. Z. Benet, N. Massoud, J. G. Gambertoglio. Raven Press, New York 1984; 119–147
- Driscoll R. C., Barr F. S., Gragg B. J., Moore G. W. Determination of therapeutic blood levels of methamphetamine and pentobarbital by GC. Journal of Pharmaceutical Sciences 1971; 60: 1492–1495
- El-Ella D. A., Neugebauer M., Eid A., Ebied M. Y., Rucker G. Stabilitatsuntersuchungen an Famprofazon-N-oxid. Archiv der Pharmazie (Weinheim) 1984; 317: 89–91
- Martindale. The Extra Pharmacopoeia, J. E. F. Reynolds. Pharmaceutical Press, London 1989; 16
- Mrongovius R., Neugebauer M., Rucker G. Analgesic activity and metabolism in the mouse of morazone, famprofazone and related pyrazolones. European Journal of Medicinal Chemistry 1984; 19: 161–166
- Neugebauer M. Some new urinary metabolites of famprofazone and morazone in man. Journal of Pharmaceutical and Biomedical Analysis 1984; 2: 53–60
- Sinniger P. A. A new antipyretic and analgesic substance: Preparation 1610 GEWO. Schweizerische Medizinische Wochenschrift 1954; 84: 351–365
- Yoshimura H., Shimeno H., Tsukamoto H. Metabolism of Drugs. LXX Further study on antipyrine metabolism. Chemical and Pharmaceutical Bulletin 1971; 19: 41–45